Polarean Imaging
Plc
("Polarean" or the "Company")
Exercise
of Warrants, PDMR Dealing, Issue of Equity and Total Voting
Rights
Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced magnetic
resonance imaging ("MRI") of the lungs, announces that it has received
notification from Dr. Bastiaan Driehuys, Chief Technology Officer
and Director, to exercise 148,456 warrants over ordinary shares in
the Company (the "Warrants"). These warrants representing 148,456
ordinary shares of £0.00037 each in the capital of the Company
("Ordinary Shares") have an exercise price of US$0.00037 per
Ordinary Share. Dr. Driehuys has indicated that he does not plan to
sell any of these shares at the present time.
After the exercise of the Warrants,
Dr. Driehuys holds a total of 12,415,959 Ordinary Shares and
options for 1,686,000 Ordinary Shares.
The 148,456 new Ordinary Shares have
been issued and admitted to trading on AIM pursuant to the Block
Listing announced by the Company on 23 July 2021. The new Ordinary
Shares will rank pari passu with the existing Ordinary
Shares.
Notifications have been made in
accordance with the requirements of the UK Market Abuse Regulation
in respect of the PDMR and further details can be found by
following this link: https://www.polarean-ir.com/content/investors/shareholder-information
Total voting rights
Following the issue and allotment of
the Ordinary Shares, the Company's issued share capital comprises
216,264,249 Ordinary Shares. The Company does not hold any Ordinary
Shares in treasury. Therefore, the total number of voting rights in
the Company is 216,264,249.
The figure of 216,264,249 may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change of their interest in, the Company under
the FCA's Disclosure Guidance and Transparency Rules.
This
announcement contains inside information for the purposes of
Article 7 of Regulation (EU) 596/2014.
Enquiries:
|
Polarean
Imaging plc
|
www.polarean.com
/ www.polarean-ir.com
|
|
Christopher von Jako, Ph.D, Chief Executive
Officer
|
Via Walbrook PR
|
|
Charles Osborne, Chief Financial
Officer
|
|
|
|
|
|
Stifel
Nicolaus Europe Limited (NOMAD and Sole Corporate
Broker)
|
+44 (0)20 7710
7600
|
|
Nicholas Moore / Samira Essebiyea / Kate
Hanshaw (Healthcare Investment Banking)
|
|
Nick Adams / Nick Harland (Corporate
Broking)
|
|
|
|
|
|
Walbrook
PR
|
Tel: +44 (0)20 7933
8780 or polarean@walbrookpr.com
|
|
Anna Dunphy / Phillip Marriage
|
Mob: +44 (0)7876 741
001 / +44 (0)7867 984 082
|
|
|
|
About
Polarean (www.polarean.com)
The Company and its wholly owned subsidiary,
Polarean, Inc. (together the "Group") are revenue-generating,
medical imaging technology companies operating in the
high-resolution medical imaging space. Polarean aspires to
revolutionise pulmonary medicine by bringing the power and safety
of MRI to the respiratory healthcare community in need of new
solutions to evaluate lung ventilation, diagnose disease,
characterise disease progression, and monitor response to
treatment. By researching, developing, and commercialising novel
imaging solutions with a non-invasive and radiation-free functional
imaging platform. Polarean's vision is to help address the global
unmet medical needs of more than 500 million patients worldwide
suffering with chronic respiratory disease. Polarean is a leader in
the field of hyperpolarisation science and has successfully
developed the first and only hyperpolarised MRI contrast agent to
be approved in the United States. The Company also commercialises
systems (such as the HPX hyperpolarisation system), accessories
(such as Xe-specific chest coils and phantoms) and FDA-cleared
post-processing software (to support ventilation defect analysis),
to support fully integrated modern respiratory imaging
operations.
PLC-RNS-2329